GALVAN Laurie

Publications HAL

Article dans une revue (19 documents)

Emmanuel Matas, Alexandre Maisterrena, Mathieu Thabault, Eric Balado, Maureen Francheteau, et al.. Major motor and gait deficits with sexual dimorphism in a Shank3 mutant mouse model. Molecular Autism, BioMed Central, 2021, 12 (1), pp.2. ⟨10.1186/s13229-020-00412-8⟩. ⟨hal-03150112⟩
Sandra Holley, Laurie Galvan, Talia Kamdjou, Carlos Cepeda, Michael Levine. Striatal GABA ergic interneuron dysfunction in the Q175 mouse model of Huntington's disease. European Journal of Neuroscience, Wiley, 2018, ⟨10.1111/ejn.14283⟩. ⟨hal-02459725⟩
Laurie Galvan, Laetitia Francelle, Marie-Claude Gaillard, Lucie de Longprez, Maria-Angeles Carrillo-de Sauvage, et al.. The striatal kinase DCLK3 produces neuroprotection against mutant huntingtin. Brain - A Journal of Neurology , Oxford University Press (OUP), 2018, 141 (5), pp.1434-1454. ⟨10.1093/brain/awy057⟩. ⟨hal-03060272⟩
Laurie Galvan, Laetitia Francelle, Marie-Claude Gaillard, Lucie de Longprez, Maria-Angeles Carrillo-de Sauvage, et al.. The striatal kinase DCLK3 produces neuroprotection against mutant huntingtin. Brain - A Journal of Neurology , Oxford University Press (OUP), 2018, 141 (5), pp.1434-1454. ⟨10.1093/brain/awy057⟩. ⟨hal-02074093⟩
Lydie Boussicault, Sandro Alves, Antonin Lamazière, Anabelle Planques, Nicolas Heck, et al.. CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington’s disease. Brain - A Journal of Neurology , Oxford University Press (OUP), 2016, 139 (3), pp.953-970. ⟨10.1093/brain/awv384⟩. ⟨hal-01299208⟩
Jamee m. Berg, Changhoon Lee, Leslie Chen, Laurie Galvan, Carlos Cepeda, et al.. JAKMIP1, a Novel Regulator of Neuronal Translation, Modulates Synaptic Function and Autistic-like Behaviors in Mouse. Neuron, Elsevier, 2015, 88 (6), pp.1173-1191. ⟨10.1016/j.neuron.2015.10.031⟩. ⟨hal-02459747⟩
Laetitia Francelle, Laurie Galvan, Marie-Claude Gaillard, Fanny Petit, Benoît Bernay, et al.. Striatal long noncoding RNA Abhd11os is neuroprotective against an N-terminal fragment of mutant huntingtin in vivo.. Neurobiology of Aging, Elsevier, 2015, pp.1601.e7-16. ⟨10.1016/j.neurobiolaging.2014.11.014⟩. ⟨hal-01465910⟩
Laetitia Francelle, Laurie Galvan, Marie-Claude Gaillard, Fanny Petit, Benoit Bernay, et al.. The striatal long noncoding RNA Abhd11os is neuroprotective against an N-terminal fragment of mutant huntingtin in vivo. Neurobiology of Aging, Elsevier, 2015, 36 (3), pp.1601.e7-1601.e16. ⟨10.1016/j.neurobiolaging.2014.11.014⟩. ⟨hal-02459770⟩
Sandra Holley, Prasad Joshi, Anna Parievsky, Laurie Galvan, Jane Chen, et al.. Enhanced GABAergic Inputs Contribute to Functional Alterations of Cholinergic Interneurons in the R6/2 Mouse Model of Huntington’s Disease. eNeuro, Society for Neuroscience, 2015, 2 (1), pp.ENEURO.0008-14.2015. ⟨10.1523/ENEURO.0008-14.2015⟩. ⟨hal-02459736⟩
Sandra Holley, Prasad Joshi, Anna Parievsky, Laurie Galvan, Jane Chen, et al.. Enhanced GABAergic Inputs Contribute to Functional Alterations of Cholinergic Interneurons in the R6/2 Mouse Model of Huntington’s Disease. eNeuro, Society for Neuroscience, 2015, 2 (1), pp.ENEURO.0008-14.2015. ⟨10.1523/ENEURO.0008-14.2015⟩. ⟨hal-02459863⟩
Laetitia Francelle, Laurie Galvan, Emmanuel Brouillet. Possible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington's disease. Frontiers in Cellular Neuroscience, Frontiers, 2014, ⟨10.3389/fncel.2014.00295⟩. ⟨hal-02459873⟩
Maria Damiano, Elsa Diguet, Carole Malgorn, Marilena d'Aurelio, Laurie Galvan, et al.. A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin. Human Molecular Genetics, Oxford University Press (OUP), 2013, 22 (19), pp.3869-3882. ⟨10.1093/hmg/ddt242⟩. ⟨hal-02459752⟩
Jane Chen, Elizabeth Wang, Laurie Galvan, My Huynh, Prasad Joshi, et al.. Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington’s Disease. PLoS Currents, Public Library of Science, 2013, ⟨10.1371/currents.hd.ec3547da1c2a520ba959ee7bf8bdd202⟩. ⟨hal-02459786⟩
Laurie Galvan, Nad'A Lepejová, Marie-Claude Gaillard, Carole Malgorn, Martine Guillermier, et al.. Capucin does not modify the toxicity of a mutant Huntingtin fragment in vivo. Neurobiology of Aging, Elsevier, 2012, 33 (8), pp.1845.e5-1845.e6. ⟨10.1016/j.neurobiolaging.2012.01.009⟩. ⟨hal-02459764⟩
Laurie Galvan, Elizabeth Wang, Carlos Cepeda, Michael Levine. Functional Differences Between Direct and Indirect Striatal Output Pathways in Huntington's Disease. Journal of Huntington's Disease, 2012, 1 (1), pp.17-25. ⟨10.3233/JHD-2012-120009⟩. ⟨hal-02459788⟩
Julie Espallergues, Laurie Galvan, Florence Sabatier, Vanessa Rana-Poussine, Tangui Maurice, et al.. Behavioral phenotyping of heterozygous acetylcholinesterase knockout (AChE+/−) mice showed no memory enhancement but hyposensitivity to amnesic drugs. Behavioural Brain Research, Elsevier, 2010, 206 (2), pp.263-273. ⟨10.1016/j.bbr.2009.09.024⟩. ⟨hal-02459760⟩
Maria Damiano, Laurie Galvan, Nicole Déglon, Emmanuel Brouillet. Mitochondria in Huntington's disease. Biochimica et Biophysica Acta - Molecular Basis of Disease, Elsevier, 2010, 1802 (1), pp.52-61. ⟨10.1016/j.bbadis.2009.07.012⟩. ⟨hal-02459756⟩
Maria Damiano, Laurie Galvan, Nicole Déglon, Emmanuel Brouillet. Mitochondria in Huntington's disease. Biochimica et Biophysica Acta - Molecular Basis of Disease, Elsevier, 2009, 1802 (1), pp.52. ⟨10.1016/j.bbadis.2009.07.012⟩. ⟨hal-00543005⟩
Julie Espallergues, Laurie Galvan, Laurence Lepourry, Béatrice Bonafos, Tangui Maurice, et al.. Hyposensitivity to the amnesic effects of scopolamine or amyloid β25–35 peptide in heterozygous acetylcholinesterase knockout (AChE+/−) mice. Chemico-Biological Interactions, Elsevier, 2008, 175 (1-3), pp.131-134. ⟨10.1016/j.cbi.2008.04.001⟩. ⟨hal-02459753⟩

Communication dans un congrès (9 documents)

S. M. Holley, Laurie Galvan, Talia Kamdjou, C. Cepeda, M. S. Levine. Somatostatin interneurons contribute towards increased striatal inhibition in the Q175 mouse model of Huntington's Disease. 46th annual meeting, neuroscientists SFN 2016, Nov 2016, SAN DIEGO, United States. ⟨hal-02534718⟩
Laurie Galvan, S. M. Holley, C. Cepeda, M. S. Levine. Altered function of Parvalbumin expressing interneurons in mouse models of Huntington’s disease. SFN 2016, Nov 2016, SAN DIEGO, United States. ⟨hal-02534713⟩
E. Brouillet, L. Francelle, Laurie Galvan, M.-C Gaillard, M.-A Carrillo-de Sauvage, et al.. Characterization of the striatal kinase Dclk3 and its neuroprotective effects against mutant huntingtin. SFN 2015, Oct 2015, CHICAGO, United States. ⟨hal-02534708⟩
Laurie Galvan, J. Berg, J Chen, C Cepeda, D Geschwind, et al.. Synaptic alterations in the striatum and the cortex of a new mouse model of autism spectrum disorders: JAKMIP1 knock-out mouse. SFN 2015, Oct 2015, CHICAGO, United States. ⟨hal-02534707⟩
J Chen, G Akopian, C Wang, Laurie Galvan, V André, et al.. Optogenetics reveal alterations in dopamine neurotransmission in the YAC128 mouse model of Huntington’s disease. SFN 2014, Nov 2014, WASHINGTON,dc, United States. ⟨hal-02534701⟩
L. Francelle, Laurie Galvan, M.-C Gaillard, G. Liot, M de Chaldée d'Abbas, et al.. The newly identified striatal marker Doublecortin-like kinase 3 (Dclk3) may be a molecular determinant of striatal vulnerability in Huntington’s disease. SFN 2013, Nov 2013, SAN DIEGO, United States. ⟨hal-02534692⟩
E. Brouillet, Laurie Galvan, M.-C Gaillard, N Lepejovà, F Petit, et al.. 2010001M06rik (St102) protects striatal neurons against an N-terminal fragment of mutant huntingtin in vivo. SFN 2012, Oct 2012, NEW ORLEANS, United States. ⟨hal-02534682⟩
Laurie Galvan, Galvan L., Gaillard M.-C., ChaldÉe M. De, Auregan G., et al.. Doublecortin-like kinase 3 (DCLK3), a novel striatum-enriched species, is a modulator of mutant huntingtin in vivo: L. GALVAN1, M.-C. GAILLARD2, M. DE CHALDÉE2, G. AUREGAN1, N. DUFOUR1, M. GUILLERMIER1, D. HOUITTE1, F. PETIT1, C. MALGORN1, G. LIOT3, S. HUMBERT3, J. ELALOUF2, N. DÉGLON1, *E. P. BROUILLET1; 1CEA, MIRCen, URA CEA-CNRS 2210, Fontenay-aux-Roses, France; 2CEAIBITec- S/SBIGeM, Saclay, France; 3Inst. Curie, UMR 146, CNRS, Orsay, France. SFN 2009, Oct 2009, CHICAGO, United States. ⟨hal-02545451⟩
Laurie Galvan, M.-C Gaillard, M. de Chaldee, G. Auregan, N. Dufour, et al.. Doublecortin-like kinase 3 (DCLK3), a novel striatum-enriched species, is a modulator of mutant huntingtin in vivo. SFN 2009, Oct 2009, CHICAGO, United States. ⟨hal-02534671⟩

Autre publication (3 documents)

Laurie Galvan. Optogenetic control of parvalbumin-expressing interneurons in the R6/2 and Q175 mouse models of Huntington’s disease. 2014. ⟨hal-02534696⟩
Laurie Galvan. Optogenetic control of parvalbumin-expressing interneurons in the R6/2 mouse model of Huntington’s disease. 2013. ⟨hal-02534687⟩
Laurie Galvan, E Richler, C Cepeda, K. Deisseroth, V. Andre, et al.. Optogenetic control of striatal fast-spiking interneurons in Huntington’s disease mouse models. 2012. ⟨hal-02534677⟩

Poster (1 document)

Laurie Galvan, Carlos Cepeda, Michael s. Levine. Optogenetic Control of Parvalbumin-Expressing Interneurons in the R6/2 Mouse Model of Huntington’s disease”. CAG Triplet Repeat Disorders - Gordon Research Conferences, Jun 2013, waterville valley, NH, United States. ⟨hal-02534733⟩

Accès directs

Menu principal

GALVAN Laurie

Publications HAL

A propos